U.S. Markets closed
  • S&P 500

    4,411.79
    +44.31 (+1.01%)
     
  • Dow 30

    35,061.55
    +238.20 (+0.68%)
     
  • Nasdaq

    14,836.99
    +152.39 (+1.04%)
     
  • Russell 2000

    2,209.65
    +10.17 (+0.46%)
     
  • Crude Oil

    72.17
    +0.26 (+0.36%)
     
  • Gold

    1,802.10
    -3.30 (-0.18%)
     
  • Silver

    25.24
    -0.14 (-0.56%)
     
  • EUR/USD

    1.1770
    -0.0003 (-0.0235%)
     
  • 10-Yr Bond

    1.2860
    +0.0210 (+1.66%)
     
  • Vix

    17.20
    -0.49 (-2.77%)
     
  • GBP/USD

    1.3754
    -0.0013 (-0.0977%)
     
  • USD/JPY

    110.5100
    +0.3950 (+0.3587%)
     
  • BTC-USD

    33,683.05
    +1,074.22 (+3.29%)
     
  • CMC Crypto 200

    786.33
    -7.40 (-0.93%)
     
  • FTSE 100

    7,027.58
    +59.28 (+0.85%)
     
  • Nikkei 225

    27,548.00
    +159.80 (+0.58%)
     

Aptose Biosciences Stock Tumbles As Luxeptinib Fails To Impress At EHA2021 Virtual Congress

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Aptose Biosciences Inc (NASDAQ: APTO) highlighted data from its luxeptinib currently in two Phase 1 a/b trials - one in relapsed or refractory acute myeloid leukemia (AML) and another in relapsed or refractory B cell malignancies.

  • In Relapsed or Refractory AML or High-Risk MDS trial, APTO-253 has been well-tolerated in the patients treated at 20, 40, 66, 100, and 150 mg/m2 over multiple cycles supporting continued dose escalation.

  • APTO-253 monomer rapidly transformed to and co-existed with the Fe(253)3 conjugate in peripheral blood.

  • Serum levels of APTO-253 and the Fe(253)3 conjugate were dose-proportional, with significantly higher Fe(253)3 conjugate concentrations than monomer.

  • In Relapsed or Refractory B-Cell Malignancies, the anti-tumor activity observed in multiple patients, including follicular lymphoma (FL), Waldenstrom’s (WM), Chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).

  • Tumor reduction in a patient with follicular lymphoma (FL) upon dose escalation from 450 mg to 600 mg.

  • IgM reduction in a patient with Waldenstrom’s (WM) at 750mg dose.

  • Dose escalation well-tolerated from 150 – 600 mg twice daily over multiple cycles.

  • One apparent dose-limiting toxicity of hypertension led to expansion at 750 mg – upon further review appears unlikely related.

  • Currently treating patients with B-cell malignancies at 750 mg BID in cohort 5; continued dose escalation planned.

  • See the slide presentation here.

  • Price Action: APTO shares are down 31.5% at $3.79 during the market session on the last check Friday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.